KM Biologics Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 2,032

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 9

KM Biologics General Information

Description

Manufacturer of biological products for disease prevention and treatment. The company produces vaccines, antitoxins, antivenoms, blood plasma products, and veterinary vaccines, enabling healthcare providers and veterinarians to prevent and treat diseases, ultimately contributing to improved life sciences and public health outcomes worldwide.

Contact Information

Formerly Known As
Kaketsuken
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 1-6-1 Okubo, Kita-ku
  • Kumamoto-shi
  • Kumamoto, 860-8568
  • Japan
+81
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Drug Discovery
Parent Company
Corporate Office
  • 1-6-1 Okubo, Kita-ku
  • Kumamoto-shi
  • Kumamoto, 860-8568
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KM Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Merger/Acquisition 02-Jul-2018 Completed Generating Revenue
To view KM Biologics’s complete valuation and funding history, request access »

KM Biologics Patents

KM Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7883079-B1 Method for thawing frozen plasma, and method for producing plasma-derived products and blood coagulation factor viii products. Active 16-Feb-2026
JP-7910205-B1 Method for producing a concentrated solution of attenuated swine parvovirus Active 09-Sep-2025
JP-7936444-B1 Method for preparing sars-cov-2 virus samples Active 03-Sep-2025
JP-7866129-B1 Method for evaluating the hardness of virus particles and method for early detection of changes in the properties of antigen particles Active 27-Aug-2025
WO-2026225638-A1 Pharmaceutical composition including blood coagulation factor x used in combination with compound for suppressing expression or activity of blood coagulation inhibitor Pending 25-Apr-2025
To view KM Biologics’s complete patent history, request access »

KM Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KM Biologics FAQs

  • Where is KM Biologics headquartered?

    KM Biologics is headquartered in Kumamoto, Japan.

  • What is the size of KM Biologics?

    KM Biologics has 2,032 total employees.

  • What industry is KM Biologics in?

    KM Biologics’s primary industry is Pharmaceuticals.

  • Is KM Biologics a private or public company?

    KM Biologics is a Private company.

  • What is KM Biologics’s current revenue?

    The current revenue for KM Biologics is .

  • When was KM Biologics acquired?

    KM Biologics was acquired on 01-Jan-2022.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process